414 related articles for article (PubMed ID: 22963661)
21. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.
Chang JY; Liu YH; Zhu Z; Welsh JW; Gomez DR; Komaki R; Roth JA; Swisher SG
Cancer; 2013 Sep; 119(18):3402-10. PubMed ID: 23798353
[TBL] [Abstract][Full Text] [Related]
25. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.
Verma V; Simone CB; Allen PK; Gajjar SR; Shah C; Zhen W; Harkenrider MM; Hallemeier CL; Jabbour SK; Matthiesen CL; Braunstein SE; Lee P; Dilling TJ; Allen BG; Nichols EM; Attia A; Zeng J; Biswas T; Paximadis P; Wang F; Walker JM; Stahl JM; Daly ME; Decker RH; Hales RK; Willers H; Videtic GM; Mehta MP; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):362-371. PubMed ID: 28011047
[TBL] [Abstract][Full Text] [Related]
26. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
[TBL] [Abstract][Full Text] [Related]
27. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity.
Duncker-Rohr V; Nestle U; Momm F; Prokic V; Heinemann F; Mix M; Reusch J; Messmer MB; Marschner N; Waller CF; Weber WA; Grosu AL
Strahlenther Onkol; 2013 Jan; 189(1):33-40. PubMed ID: 23179248
[TBL] [Abstract][Full Text] [Related]
29. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
[TBL] [Abstract][Full Text] [Related]
30. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
Bilal H; Mahmood S; Rajashanker B; Shah R
Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.
Trovo M; Minatel E; Durofil E; Polesel J; Avanzo M; Baresic T; Bearz A; Del Conte A; Franchin G; Gobitti C; Rumeileh IA; Trovo MG
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1114-9. PubMed ID: 24661664
[TBL] [Abstract][Full Text] [Related]
32. SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.
Kwak YK; Park HH; Choi KH; Park EY; Sung SY; Lee SW; Hong JH; Lee HC; Yoo IR; Kim YS
Cancer Res Treat; 2020 Jan; 52(1):85-97. PubMed ID: 31122008
[TBL] [Abstract][Full Text] [Related]
33. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
Abelson JA; Murphy JD; Trakul N; Bazan JG; Maxim PG; Graves EE; Quon A; Le QT; Diehn M; Loo BW
Lung Cancer; 2012 Dec; 78(3):219-24. PubMed ID: 23009727
[TBL] [Abstract][Full Text] [Related]
34. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer.
Hayashi S; Tanaka H; Kajiura Y; Ohno Y; Hoshi H
Radiat Oncol; 2014 Jun; 9():138. PubMed ID: 24935216
[TBL] [Abstract][Full Text] [Related]
37. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
[TBL] [Abstract][Full Text] [Related]
38. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
Mahmood S; Bilal H; Faivre-Finn C; Shah R
Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
[TBL] [Abstract][Full Text] [Related]
39. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
van den Berg LL; Klinkenberg TJ; Groen HJM; Widder J
J Thorac Oncol; 2015 May; 10(5):826-831. PubMed ID: 25629639
[TBL] [Abstract][Full Text] [Related]
40. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
